Central Clinical School, Monash University, Melbourne.
Department of Infectious Diseases, The Alfred Hospital, Alfred Health, Prahran.
Clin Infect Dis. 2018 Nov 28;67(12):1847-1852. doi: 10.1093/cid/ciy370.
To determine participants' human immunodeficiency virus (HIV) risk, the Australian preexposure prophylaxis (PreEPX) trial used 6 eligibility criteria derived from the US Centers for Disease Control and Prevention PrEP guidelines. Participants who fulfilled no eligibility criteria could be enrolled if clinically assessed to need PrEP. This study evaluated whether PREPX eligibility criteria correlated with biological HIV risk markers-namely, syphilis, anorectal chlamydia, or anorectal gonorrhea (sexually transmitted infections [STIs]).
We calculated adjusted odds ratios (aORs) to assess whether eligibility criteria predicted STI diagnoses at enrollment.
We included 1774 participants, of whom 10.2% tested positive for STIs. Eligibility criteria predicted STI diagnoses as follows: (1) aOR 2.5 (95% confidence interval [CI], 1.4-4.4) for condomless anal intercourse (CLAI) with an HIV-positive regular sexual partner (RSP) with detectable viral load; (2) aOR 1.8 (95% CI, 1.3-2.5) for receptive CLAI with casual sexual partners; (3) aOR 1.8 (95% CI, 1.3-2.5) for previous STIs; (4) aOR 2.1 (95% CI, 1.4-3.0) for methamphetamine use; (5) aOR 0.8 (95% CI, .6-1.1) for unsuccessful condom use; and (6) aOR 1.0 (95% CI, .7-1.4) for insertive CLAI when uncircumcised. Of participants enrolled outside eligibility criteria, 7.1% had STIs.
Eligibility criteria 1-4 predicted diagnoses of STIs, but eligibility criteria 5 and 6 did not. Our findings support the use of PrEP eligibility criteria recommended in current guidelines. Participants enrolled outside the eligibility criteria had substantial prevalence of STIs, suggesting that people who request PrEP but do not fulfill eligibility criteria may nonetheless need PrEP.
为了确定参与者的人类免疫缺陷病毒(HIV)风险,澳大利亚的暴露前预防(PreEPX)试验使用了 6 项来自美国疾病控制与预防中心 PrEP 指南的资格标准。如果临床评估需要 PrEP,那么没有满足任何资格标准的参与者也可以入组。本研究评估了 PreEPX 资格标准是否与生物 HIV 风险标志物相关,即梅毒、直肠衣原体或直肠淋病(性传播感染[STI])。
我们计算了调整后的优势比(aOR),以评估资格标准是否预测了入组时的 STI 诊断。
我们纳入了 1774 名参与者,其中 10.2%的人 STI 检测呈阳性。资格标准预测了 STI 诊断如下:(1)与 HIV 阳性的固定性伴侣(RSP)发生无保护的肛交(CLAI)且 RSP 病毒载量可检测时,aOR 为 2.5(95%置信区间[CI],1.4-4.4);(2)与偶然的性伴侣发生接受性 CLAI 时,aOR 为 1.8(95%CI,1.3-2.5);(3)有既往 STI 病史时,aOR 为 1.8(95%CI,1.3-2.5);(4)使用甲基苯丙胺时,aOR 为 2.1(95%CI,1.4-3.0);(5)避孕套使用失败时,aOR 为 0.8(95%CI,.6-1.1);(6)未行包皮环切术时,作为插入性 CLAI 的一方,aOR 为 1.0(95%CI,.7-1.4)。在不符合资格标准的情况下入组的参与者中,有 7.1%的人患有 STI。
资格标准 1-4 预测了 STI 的诊断,但标准 5 和 6 没有。我们的研究结果支持使用现行指南中推荐的 PrEP 资格标准。不符合资格标准的参与者中 STI 的患病率较高,这表明请求 PrEP 但不符合资格标准的人可能仍需要 PrEP。